#Bioretec #Finland #Tampere #RemeOs #TPT Status

Bioretec's Groundbreaking Achievement in Orthopedic Care

In a significant development for the orthopedic community, Bioretec Ltd, recognized as a trailblazer in absorbable orthopedic implants, has received Transitional Pass-Through Payment (TPT) status from the U.S. Centers for Medicare & Medicaid Services (CMS) for its innovative product, the RemeOs™ Trauma Screw. This status, effective from October 1, 2025, is a pivotal moment for advancing orthopedic treatment and patient care.

The TPT payment is an essential mechanism that provides hospitals and ambulatory surgical centers with increased reimbursement for adopting innovative medical technologies. By offering a billing code (HCPCS code C1741) specific to the RemeOs™ Trauma Screw, CMS has created a pathway to support healthcare providers in offsetting the costs associated with integrating new technologies into practice.

The recent update to the HCPCS Level II codes, which took effect on January 1, 2026, included a revised descriptor for code C1741. The updated language clarifies that the code pertains specifically to “Anchor/screw bone fixation, absorbable, metallic (implantable).” This precision aligns with the regulatory framework established by the FDA, confirming the compatibility of the RemeOs™ Trauma Screw with existing classifications of absorbable metallic bone fixation implants.

The RemeOs™ Trauma Screw stands out as the first and only osteopromotive absorbable metal implant available for orthopedic use in the United States. The implant is uniquely designed to support the natural healing process of bones, as it is absorbed by the body over time, thereby circumventing the long-term risks and costs typically associated with permanent metallic implants. This innovative approach not only enhances clinical outcomes but also offers a safer treatment option with fewer complications for patients.

This transformative product has already garnered the attention of medical professionals since it’s backed by Breakthrough Device Designation from the FDA and has successfully navigated the De Novo market authorization pathway. This recognition highlights the value that Bioretec brings to the field of orthopedic medicine by introducing solutions that improve patient experiences and outcomes.

The evolution of the HCPCS code C1741 signals Bioretec’s strategic advantage as one of the very few companies recognized by both regulatory bodies and payers. This acknowledgment is not just a testament to the innovation behind the RemeOs™ Trauma Screw, but it also serves as a significant leap towards improving accessibility for patients who require advanced orthopedic care.

As Bioretec continues to revolutionize orthopedic treatment through its commitment to biodegradable implant technologies, the implications of the TPT status extend beyond financial reimbursement. It resonates with a broader objective to promote patient access to the latest surgical solutions, ultimately aiming to alleviate barriers that healthcare providers face in adopting new technologies.

The RemeOs™ product line leverages a high-performance magnesium alloy and hybrid composite, representing a new generation of absorbable materials with the potential to significantly improve surgical results. The focus on developing implants that merge seamlessly with the body’s biological processes reflects Bioretec's vision for the future of orthopedic care – one that prioritizes healing through absorption while paving the way for more patient-friendly solutions.

In conclusion, Bioretec’s achievement in securing TPT status for the RemeOs™ Trauma Screw is not merely a corporate milestone. It is a transformative shift in how orthopedic care can be delivered, with a focus on innovation, efficiency, and enhanced patient outcomes. As more healthcare facilities embrace these advancements, it is expected that patient access to cutting-edge orthopedic treatments will expand, marking a new era in orthopedic surgery.